A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults

Recruiting now · Phase 1

Conditions studied: Influenza, Human+COVID-19

In brief

This early-stage study will look at a new mRNA vaccine that combines defenses against both seasonal flu and COVID-19 in terms of its safety and how it builds protection. Healthy adults aged 65 to 85 will receive different doses of this new vaccine, a standard flu vaccine, or COVID-19 vaccine. The study will assess any side effects or health issues, and additional blood samples will be collected at specific times to evaluate how well participants bodies build protection against the flu and COVID-19.

Key facts

Study ID

NCT07464314

Run by

GlaxoSmithKline

People needed

225

Starts

2026-03-09

Expected to finish

2027-06-03

Last updated by the study team

2026-06-30

Who can join

Age: 65 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants, who, in the opinion of the investigator, can and will comply with the requirements of the protocol independently or with the assistance of the caregiver.
• Informed consent obtained from the participant prior to performance of any study-specific procedure.
• A male or female 65 to 85 years of age (YoA) (inclusive) at the time of screening.
• Healthy participants or medically stable patients as established by medical history and clinical examination.
• Other protocol-defined inclusion criteria may apply.

You may not qualify if…

• Any clinically significant laboratory abnormality.
• History of symptomatic influenza/ SARS-CoV-2 infection confirmed by local health authority-approved testing methods within 180 days (for influenza) or 90 days (SARS-CoV-2 infection) prior to study intervention administration.
• History of Guillain-Barré syndrome (GBS) within 6 weeks of receiving any vaccine.
• Current or past malignancy, unless completely resolved without clinically significant sequelae (e.g., no evidence of disease following successful treatment of basal cell carcinoma cases are allowed) for >5 years.
• Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
• History of or current suspicion of myocarditis or pericarditis (including following administration of an mRNA vaccine); or idiopathic cardiomyopathy, or presence of any medical condition that increases the risk of myocarditis or pericarditis, including cocaine abuse, cardiomyopathy, endomyocardial fibrosis, hypereosinophilic syndrome, hypersensitivity myocarditis, eosinophilic granulomatosis with polyangiitis and persistent myocardial infection.
• History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s).
• Acute or unstable chronic conditions, clinically significant pulmonary, cardiovascular, or renal functional abnormality, as determined by physical examination and/or laboratory screening tests.
• History of hypersensitivity or allergic reaction to any previous influenza or COVID-19 vaccine.
• History of hypersensitivity or allergic reaction to any previous mRNA vaccine.
• Administration of any influenza vaccine within 181 days before the study intervention administration (Day -180 to Day 1) or planned administration within 28 days (Day 29) after the study intervention administration.
• Administration of a SARS-CoV-2 antigen-containing vaccine in the period starting 91 days before the study intervention administration (Day -90 to Day 1) or planned administration within 28 days (Day 29) after the study intervention administration.
• Administration of any mRNA-based vaccine in the period starting 29 days before the study intervention administration (Day -28 to Day 1) or planned administration within 28 days (Day 29) after the study intervention administration.
• Administration of any other vaccine not foreseen by the study protocol in the period starting 29 days (Day -28 to Day 1) before the study intervention administration or planned administration within 28 days (Day 29) after the study intervention administration.
• Other protocol-defined exclusion criteria may apply.

Where it is running

• GSK Investigational Site — Anniston, Alabama, United States (enrolling)
• GSK Investigational Site — Little Rock, Arkansas, United States (enrolling)
• GSK Investigational Site — Fair Oaks, California, United States (enrolling)
• GSK Investigational Site — San Diego, California, United States (enrolling)
• GSK Investigational Site — Miami, Florida, United States (enrolling)
• GSK Investigational Site — Miami Lakes, Florida, United States (enrolling)
• GSK Investigational Site — West Palm Beach, Florida, United States (enrolling)
• GSK Investigational Site — Stockbridge, Georgia, United States (enrolling)
• GSK Investigational Site — Austin, Texas, United States (enrolling)
• GSK Investigational Site — Charlottesville, Virginia, United States (enrolling)
• GSK Investigational Site — Newport News, Virginia, United States (enrolling)
• GSK Investigational Site — Seattle, Washington, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.